Peralta-Arrieta I, Armas-López L, Zúñiga J, Ávila-Moreno F. Epigenetics in non-small cell lung carcinomas. Salud Publica Mex. 2019;61:318–28. https://doi.org/10.21149/10089.

Article  PubMed  Google Scholar 

Nasim F, Sabath BF, Eapen GA. Lung cancer. Med Clin North Am. 2019;103:463–73. https://doi.org/10.1016/j.mcna.2018.12.006.

Article  PubMed  Google Scholar 

Lim JU, Yeo CD, Rhee CK, Kang HS, Park CK, Kim JS, Kim JW, Kim SJ, Yoon HK, Lee SH. Comparison of clinical characteristics and overall survival between spirometrically diagnosed chronic obstructive pulmonary disease (COPD) and non-COPD never-smoking stage I-IV non-small cell lung cancer patients. Int J Chron Obstruct Pulmon Dis. 2019;14:929–38. https://doi.org/10.2147/copd.s190244.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sgambato A, Casaluce F, Maione P, Gridelli C. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors. Expert Rev Anticancer Ther. 2018;18:71–80. https://doi.org/10.1080/14737140.2018.1412260.

Article  CAS  PubMed  Google Scholar 

Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7:387–401. https://doi.org/10.1016/s2213-2600(19)30084-0.

Article  CAS  PubMed  Google Scholar 

Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Lee JS, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379:2027–39. https://doi.org/10.1056/nejmoa1810171.

Article  CAS  PubMed  Google Scholar 

Ruiz-Cordero R, Devine WP. Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin. 2020;13:17–33. https://doi.org/10.1016/j.path.2019.11.002.

Article  PubMed  Google Scholar 

Coomer AO, Black F, Greystoke A, Munkley J, Elliott DJ. Alternative splicing in lung cancer. Biochim Biophys Acta Gene Regul Mech. 2019;1862:194388. https://doi.org/10.1016/j.bbagrm.2019.05.006.

Article  CAS  PubMed  Google Scholar 

Jin M, Liu B, Chen C, Huang Y, Zhang H, Chen B, et al. Genome-wide splicing quantitative expression locus analysis identifies causal risk variants for non-small cell lung cancer. Cancer Res. 2023;83(10):1742–56. https://doi.org/10.1158/0008-5472.can-22-3184.

Article  CAS  PubMed  Google Scholar 

Wang X, Codreanu SG, Wen B, Li K, Chambers MC, Liebler DC, Zhang B. Detection of proteome diversity resulted from alternative splicing is limited by trypsin cleavage specificity. Mol Cell Proteomics. 2018;17:422–30. https://doi.org/10.1074/mcp.ra117.000155.

Article  CAS  PubMed  Google Scholar 

El Marabti E, Younis I. The cancer spliceome: reprograming of alternative splicing in cancer. Front Mol Biosci. 2018;5:80. https://doi.org/10.3389/fmolb.2018.00080.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, et al. Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell. 2018;34:211-224.e6. https://doi.org/10.1016/j.ccell.2018.07.001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baldacci S, Kherrouche Z, Descarpentries C, Wislez M, Dansin E, Furlan A, et al. MET exon 14 splicing sites mutations: a new therapeutic opportunity in lung cancer. Rev Mal Respir. 2018;35:796–812. https://doi.org/10.1016/j.rmr.2018.01.011.

Article  CAS  PubMed  Google Scholar 

Zheng M, Niu Y, Bu J, Liang S, Zhang Z, Liu J, Guo L, Zhang Z, Wang Q. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling. Aging (Albany NY). 2021;13(3):3554–72. https://doi.org/10.18632/aging.202295.

Article  CAS  PubMed  Google Scholar 

Vander Borght A, Duysinx M, Broers JLV, Ummelen M, Falkenberg FW, Hahnel C, van der Zeijst BAM. The 180 splice variant of NCAM-containing exon 18-is specifically expressed in small cell lung cancer cells. Transl Lung Cancer Res. 2018;7(3):376–88. https://doi.org/10.21037/tlcr.2018.03.03.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ule J, Blencowe BJ. Alternative splicing regulatory networks: functions, mechanisms, and evolution. Mol Cell. 2019;76:329–45. https://doi.org/10.1016/j.molcel.2019.09.017.

Article  CAS  PubMed  Google Scholar 

Bijen HM, van der Steen DM, Hagedoorn RS, Wouters AK, Wooldridge L, Falkenburg JHF, et al. Preclinical strategies to identify off-target toxicity of high-affinity TCRs. Mol Ther. 2019;26:1206–14. https://doi.org/10.1016/j.ymthe.2018.02.017.

Article  CAS  Google Scholar 

Payer LM, Steranka JP, Ardeljan D, Walker J, Fitzgerald KC, Calabresi PA, et al. Alu insertion variants alter mRNA splicing. Nucleic Acids Res. 2019;47:421–31. https://doi.org/10.1093/nar/gky1086.

Article  CAS  PubMed  Google Scholar 

Frankiw L, Baltimore D, Li G. Alternative mRNA splicing in cancer immunotherapy. Nat Rev Immunol. 2019;19:675–87. https://doi.org/10.1038/s41577-019-0195-7.

Article  CAS  PubMed  Google Scholar 

Deng K, Yao J, Huang J, Ding Y, Zuo J. Abnormal alternative splicing promotes tumor resistance in targeted therapy and immunotherapy. Transl Oncol. 2021;14(6):101077. https://doi.org/10.1016/j.tranon.2021.101077.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao B, Xiang Z, Wu B, Zhang X, Feng N, Wei Y, Zhang W. Use of novel m6A regulator-mediated methylation modification patterns in distinct tumor microenvironment profiles to identify and predict glioma prognosis and progression, T-cell dysfunction, and clinical response to ICI immunotherapy. Curr Pharm Des. 2023;29(1):60–78. https://doi.org/10.2174/1381612829666221207112438.

Article  CAS  PubMed  Google Scholar 

Li N, Wang J, Zhan X. Identification of immune-related gene signatures in lung adenocarcinoma and lung squamous cell carcinoma. Front Immunol. 2021;12:752643. https://doi.org/10.3389/fimmu.2021.752643.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhattacharya S, Andorf S, Gomes L, Dunn P, Schaefer H, Pontiuset J, et al. ImmPort: disseminating data to the public for the future of immunology. Immunol Res. 2014;58:234–9. https://doi.org/10.1007/s12026-014-8516-1.

Article  CAS  PubMed  Google Scholar 

Banerjee S, Galarza-Muñoz G, Garcia-Blanco MA. Role of RNA alternative splicing in T cell function and disease. Genes (Basel). 2023;14(10):1896. https://doi.org/10.3390/genes14101896.

Article  CAS  PubMed  Google Scholar 

Meazza R, Verdiani S, Biassoni R, Coppolecchia M, Gaggero A, Orengo AM, et al. Identification of a novel interleukin-15 (IL-15) transcript isoform generated by alternative splicing in human small cell lung cancer cell lines. Oncogene. 1996;12:2187–92.

CAS  PubMed  Google Scholar 

Tano V, Jans DA, Bogoyevitch MA. Oligonucleotide-directed STAT3 alternative splicing switch drives anti-tumorigenic outcomes in MCF10 human breast cancer cells. Biochem Biophys Res Commun. 2019;513:1076–82. https://doi.org/10.1016/j.bbrc.2019.04.054.

Article  CAS  PubMed  Google Scholar 

Zhao S, Chang SL, Linderman JJ, Feng FY, Luker GD. A comprehensive analysis of CXCL12 isoforms in breast cancer (1,2). Transl Oncol. 2014;7:429–38. https://doi.org/10.1016/j.tranon.2014.04.001.

Article  PubMed  PubMed Central  Google Scholar 

Han N, Liu Z. Targeting alternative splicing in cancer immunotherapy. Front Cell Dev Biol. 2023;11:1232146. https://doi.org/10.3389/fcell.2023.1232146.

Article  PubMed  PubMed Central  Google Scholar 

Golubnitschaja O, Costigliola V, EPMA. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012;3(1):14. https://doi.org/10.1186/1878-5085-3-14.

Article  PubMed  PubMed Central  Google Scholar 

Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis. Int J Mol Sci. 2021;22(16):8661. https://doi.org/10.3390/ijms22168661.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li N, Zhan X. Signaling pathway network alterations in human ovarian cancers identified with quantitative mitochondrial proteomics. EPMA J. 2019;10:153–72. https://doi.org/10.1007/s13167-019-00170-5.

Article  PubMed  PubMed Central  Google Scholar 

Karatza E, Papachristos A, Sivolapenko GB, Gonzalez D. Machine learning-guided covariate selection for time-to-event models developed from a small sample of real-world patients receiving bevacizumab treatment. CPT Pharmacometrics Syst Pharmacol. 2022;11(10):1328–40. https://doi.org/10.1002/psp4.12848.

Article  CAS  PubMed  PubMed Central